Myriad wins US patent for p19 gene:
This article was originally published in Clinica
Myriad Genetics has received a US patent covering the DNA sequence of the tumour suppressor gene p19, otherwise known as MTS2. The patent also covers primers, probes and vectors relating to the use of the p19 gene in diagnostic and therapeutic products. The p19 gene is an important regulator of the p53 cancer pathway, said the Salt Lake City, Utah-based company. p53, the most common tumour suppressor gene, is mutated in over half of all types of cancer.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.